Table 4.
A summary of astrocytes-targeting platforms reported in recent studies.
| Targeted cells | Platform | Route of administration | Delivered therapeutics? | Model of
evaluation/Application |
Effects on targeted cells |
|---|---|---|---|---|---|
| Astrocytes | Lentiviral Vector [135] | Intracranial | Gene | Healthy mouse | Transfection |
|
| |||||
| Astrocytes | Lentiviral Vector [136] | Intracranial | Gene | Healthy rat | Transfection |
|
| |||||
| Astrocytes | Adeno-Associated Virus (AAV) [138] |
Intracranial | Astrocyte-specific Gfa2
promoter |
Mouse Model of Alzheimer’s
Disease |
Reduced glia activation |
|
| |||||
| Astrocytes | Iron oxide, silver nanoparticles [139] |
- | No | in vitro | N/A |
|
| |||||
|
Microglia, Astrocytes,
Oligodendrocytes |
Carboxymethylchitosan/polya
midoamine (CMCht/PAMAM) dendrimer [140] |
- | No | in vitro | N/A |
|
| |||||
| Astrocytes, neurons | PLGA nanoparticles[141] | Intraspinal | Neurotrophic factor (GDNF) | Spinal cord injury | N/A |
|
| |||||
| Astrocytes, microglia | Hydroxyl terminated G4 PAMAM Dendrimer [104] |
Intravenous | NAC | CP | Reduced glia activation |
|
| |||||
| Astrocytes, Oligodendrocytes | Hydroxyl terminated G4 PAMAM Dendrimer [90] |
Intravenous | NAC | Mouse model of Ischemia- induced neonatal white matter injury |
N/A |
For each platform; delivered therapeutics; model of evaluation/application and effects on targeted cells are described.